Cost-effectiveness of combining finerenone and sodium-glucose cotransporter 2 inhibitors with standard of care for patients with chronic kidney disease and type 2 diabetes in China. [PDF]
Hu Z, Jin W, Lou S, Zhang L.
europepmc +1 more source
Comparative effectiveness of biguanides versus SGLT2 inhibitors on cardiovascular and cerebrovascular events, diabetic nephropathy, retinopathy, neuropathy, and treatment expenditures in patients with type 2 diabetes. [PDF]
Nakatani E +15 more
europepmc +1 more source
Sodium-Glucose Cotransporter 2 Inhibitors
openaire +2 more sources
Exploring the Cell Biological and Functional Effects of the First Disease Associated KCC1 Genetic Variant. [PDF]
Bloothooft M +9 more
europepmc +1 more source
Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Atrial Fibrillation: Clinical Implications, Mechanisms, and Therapeutic Potential. [PDF]
Ramadan MM +14 more
europepmc +1 more source
Sodium-glucose cotransporter-2 inhibitors and the risk of all-cause mortality: a population-based cohort study using the UK Clinical Practice Research Datalink. [PDF]
Eroglu TE, Coronel R, Souverein PC.
europepmc +1 more source
Sodium-Glucose Cotransporter 2 Inhibitors-Induced Euglycemic Ketoacidosis Mimicking Myocardial Infarction in a Non-Diabetic Heart Failure Patient. [PDF]
Pack K, Ha KE, Yang T, Chung WJ.
europepmc +1 more source
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors and Risk of Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]
Joher I +10 more
europepmc +1 more source
Transport and thiazide-inhibition mechanisms of the Na-Cl cotransporter: a structural perspective
Chien-Ling Lee, Liang Feng
openalex +1 more source

